Updates are available Addendum dated 2017-06-22
Click to view Addendum: https://doi.org/10.1038/nature22809
-
Authors
Sevigny, Jeff
Chiao, Ping
Bussière, Thierry
Weinreb, Paul H.
Williams, Leslie
Maier, Marcel
Dunstan, Robert
Salloway, Stephen
Chen, Tianle
Ling, Yan
O’Gorman, John
Qian, Fang
Arastu, Mahin
Li, Mingwei
Chollate, Sowmya
Brennan, Melanie S.
Quintero-Monzon, Omar
Scannevin, Robert H.
Arnold, H. Moore
Engber, Thomas
Rhodes, Kenneth
Ferrero, James
Hang, Yaming
Mikulskis, Alvydas
Grimm, Jan
Hock, Christoph
Nitsch, Roger M.
Sandrock, Alfred
- License Information
-
More Information
Article History
Received: 20 July 2015
Accepted: 21 July 2016
First Online: 31 August 2016
Competing interests
: J.S., P.C., T.B., P.H.W., L.W., R.D., T.C., Y.L., J.O., F.Q., M.A., M.L., S.C., M.S.B., O.Q.-M., R.H.S., H.M.A., T.E., K.R., J.F., Y.H., A.M. and A.S. are current or former employees and/or shareholders of Biogen. J.S. is an employee of F. Hoffmann-La Roche Ltd., Basel, Switzerland; R.D. is an employee of AbbVie Inc., Worcester, Massachusetts, USA; M.A. is an employee of Substantial Living, San Francisco, California, USA; M.L. is an employee of Novartis, Cambridge, Massachusetts, USA; S.C. is an employee of SynteractHCR, Carlsbad, California, USA; O.Q.-M. is an employee of Shire, Lexington, Massachusetts, USA; R.H.S. and K.R. are employees of Yumanity Therapeutics, Cambridge, Massachusetts, USA; T.E. is an employee of Takeda Pharmaceuticals, Cambridge, Massachusetts, USA; J.F. is retired. M.M., J.G., C.H. and R.M.N. are employees and shareholders of Neurimmune. S.S. was a site investigator for the PRIME study and received consultation fees from Biogen, and has received research support from Functional Neuromodulation, Merck, Genentech, Roche, Lilly, and Avid Radiopharmaceuticals, and consultation fees from Merck, Piramal, Lilly, Genentech, and Roche. He owns no stock options or royalties. Biogen has filed and licensed certain patent applications pertaining to Aducanumab.
